Earnings Analysis November 1, 2026

Astrazeneca plc ($AZN) Q3 2026 Earnings Analysis: Core EPS of $2.79 Beats Estimates, Annual Guidance Maintained

Earnings Report

Revenue: $16.209 billion (up 7% YoY, vs. $16.665 billion expected) ❌ Miss

EPS (Earnings Per Share): Core EPS $2.79, reported EPS $2.02 (vs. $2.60 expected) ✅ Beat

Guidance: Maintained + mid-to-high single-digit growth in total annual revenue for 2026, low double-digit growth in core EPS, and a core tax rate of 18-22%

Stock Reaction: +7.0% (based on BMO closing price for the day)

Highlights

Core EPS of $2.79: Exceeded the $2.60 estimate by $0.19, representing a 17% increase year-over-year.

Oncology Revenue of $7.765 billion: The oncology division grew 17% year-over-year in Q3 2026.

Reaffirmed Annual Outlook: Maintained mid-to-high single-digit growth in total revenue and low double-digit growth in core EPS.

While patent expirations for Farcipa and Brilinta dragged down revenue, oncology, rare diseases, and respiratory/immunology offset the decline. Total revenue for the nine-month period, excluding these two items, increased by 12%.

Lowlights

Revenue Miss: At $16.209 billion, it fell 2.7% short of the $16.665 billion expected.

18% Decline in Cardiovascular, Renal, and Metabolism: Farcipa revenue fell 25% to $1.605 billion.

Two Phase 3 Discontinuations: Phase 3 trials for Volustomig in lung cancer and Ultomiris in transplanted kidney were each discontinued.

Etcama's Phase 3 trial for first-line treatment failed to demonstrate improvement in progression-free survival. The company will invest up to $2 billion in one-time costs for a three-year restructuring.

What the Company Said

Chief Executive Officer Pascal Soriot explained that nine-month total revenue and core EPS increased by 7% and 14%, respectively, and that the maximum revenue potential from major Phase 3 results in 2027 exceeds $20 billion. The company reaffirmed its annual outlook at previous levels and stated that it would generate $1.5 billion in annual pre-tax savings through a three-year restructuring to reinvest in its pipeline.

Market Reaction and Future Key Points

This was a quarter where core earnings per share exceeded expectations and the annual guidance remained unchanged. Starting from the previous closing price of $174.40, the stock closed at $186.65 on the day of the announcement.

A key point will be to see if oncology sales offset the generic pressure from Parsiga and Symbicort in the fourth quarter.

It is worth watching how the restructuring costs of up to $2 billion will be reflected in the 2027 operating margin.

Among more than 20 Phase 3 results in 2027, the U.S. launch of torzomab is the first hurdle.

Earnings Call Key Summary

We have summarized the key points from the AstraZeneca earnings call.

[Neutral] Large-scale Restructuring: A plan to reorganize the organization over several years. While it will incur high initial costs, the savings will be reinvested into new drug development. This means it is a preparation for the future rather than an immediate increase in profits. Why UST viewed it as neutral: Because the savings will be reinvested into new drug development. "This program is expected to incur up to $2 billion in one-time restructuring costs and yield $1.5 billion in annual pre-tax savings." (Astrazeneca Aradana)

[Bullish] Imfinzi Subcutaneous: Imfinzi is currently administered via intravenous injection. The company plans to release a new subcutaneous version before patent expiration. This is an attempt to protect existing revenue with a more convenient injection. Why UST viewed it as bullish: Because revenue will be protected with a new formulation before patent expiration. "The Imfinzi subcutaneous program is progressing smoothly, and we expect to launch the subcutaneous version before the patent expiration of Imfinzi." (Astrazeneca Dave)

[Bullish] Value Increase Despite Failures: Although there were clinical trial failures this year, the explanation is that when successful results are added, the overall value of the drug candidates has actually increased. This means a single failure is not enough to shake the entire company. Why UST viewed it as bullish: Because the successful results offset the failures and more. "Graham, looking at Net Present Value (NPV), there is no doubt that the value has actually increased even after excluding the two failed studies, Wainua and Serena-4." (Astrazeneca Pascal)